Shopping Cart
- Remove All
- Your shopping cart is currently empty
BPK-29, a ligand specifically targeting the atypical orphan nuclear receptor NR0B1, disrupts its protein interactions through covalent modification at C274, thereby impairing the anchorage-independent growth of KEAP1-mutant cancer cells.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 1-2 weeks | |
50 mg | $1,980 | 1-2 weeks | |
100 mg | $2,500 | 1-2 weeks |
Description | BPK-29, a ligand specifically targeting the atypical orphan nuclear receptor NR0B1, disrupts its protein interactions through covalent modification at C274, thereby impairing the anchorage-independent growth of KEAP1-mutant cancer cells. |
In vitro | BPK-29 effectively targets NR0B1, demonstrating considerable proteomic selectivity within KEAP1-mutant Non-Small Cell Lung Cancers (NSCLCs)[1]. |
Molecular Weight | 470 |
Formula | C26H32ClN3O3 |
Cas No. | 2143467-62-1 |
Relative Density. | 1.26 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.